small molecule

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

MIDAZOLAM

Loss of exclusivityJune 2038latest FDA-listed patent expiry
CompanyINFORLIFE SA

Drug detail

Brand nameMIDAZOLAM IN 0.9% SODIUM CHLORIDE
Active ingredientMIDAZOLAM
Strength50MG/50ML (1MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2021
Marketing statusRX

Listed patents

PatentExpiresType
10966990June 2038product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MIDAZOLAM IN 0.9% SODIUM CHLORIDE patent cliff — loss of exclusivity June 2038 | CliffBio